PDE1 Inhibitors Treat Colon Cancer, USPTO Grant
Summary
The USPTO granted Patent US12599603B2 to Intra-Cellular Therapies, Inc. covering phosphodiesterase 1 (PDE1) inhibitors for the treatment of colon cancer and certain tumors. The patent, with inventors Peng Li and Robert Davis, claims 12 method-of-treatment claims. The application was filed on September 3, 2020.
What changed
The USPTO issued Patent US12599603B2 to Intra-Cellular Therapies, Inc. for methods of treating colon cancer and certain tumors using phosphodiesterase 1 (PDE1) inhibitors, either alone or in combination with antitumor agents. The patent includes 12 claims covering the therapeutic methods.
For pharmaceutical and biotech companies developing cancer treatments, this patent establishes enforceable intellectual property rights that may limit competitive development of similar PDE1 inhibitor therapies for the specified indications. Patent holders gain exclusive commercial rights for the claimed treatment methods.
What to do next
- Monitor for updates
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods of treatment
Grant US12599603B2 Kind: B2 Apr 14, 2026
Assignee
INTRA-CELLULAR THERAPIES, INC.
Inventors
Peng Li, Robert Davis
Abstract
The disclosure relates to the combination of inhibitors of phosphodiesterase 1 (PDE1) useful for the treatment of certain cancers or tumors, such as colon cancer. In another embodiment, the disclosure relates to the use of inhibitors of PDE1 and an optional antitumor agent for the treatment of certain cancers or tumors.
CPC Classifications
A61K 31/519 A61K 31/505 A61K 38/005 A61P 35/00
Filing Date
2020-09-03
Application No.
17640050
Claims
12
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.